All In Biotech

Free tool

FAERS Monitor: Alhemo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761315 or its brand name (Alhemo, Concizumab-Mtci). Reports on generic versions are filed under their own applications.

Reports

45

Serious

36

80% of reports

Hospitalization

17

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemarthrosis11
  • fall4
  • condition aggravated3
  • haematoma muscle3
  • injection site pain3
  • muscle haemorrhage3
  • anti factor ix antibody increased2
  • contusion2
  • death2
  • haematoma2
  • haematuria2
  • haemorrhage2
  • haemorrhage subcutaneous2
  • off label use2
  • scleritis2

Reports by year received

View as table
YearReports
20241
202527
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anti factor ix antibody increased258483.713847.158,481
haematoma muscleSignal31173.6392.72,434
scleritis2584.5150.7654
haemarthrosisSignal11574.4343.55,731
muscle haemorrhageSignal3349.7117.1723
haemorrhage subcutaneous2263.768.0294
haematoma236.19.338
haematuria227.37.028
contusion29.72.58
haemorrhage28.92.37
fallSignal45.62.211
condition aggravatedSignal34.61.55
injection site painSignal34.61.55
death21.10.30
off label use21.10.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.